US FDA criticised over application handling:
This article was originally published in Clinica
Citizens for a Sound Economy Foundation, a business-oriented public policy group, last week criticised the US FDA for its handling of medical device PMA applications. The group noted that, in fiscal 1996, the FDA approved 43 PMA applications with an average review time of 789 days, nearly four-and-a-half times the legal requirement. CSEF, a vocal advocate for FDA reform, also believes the agency could improve its processing of 510(k) notifications.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.